JMP holds Sangamo at market outperform

Sangamo BioSciences, Inc. was maintained by JMP Securities analyst Charles C. Duncan at market outperform, with a price target of $8 per share after an investor presentation that highlighted the biopharmaceutical company's Zink Finger Protein. JMP said the company set new goals for the foreseeable future for its clinical activity and pointed to new corporate collaborations. Shares of the Richmond, Calif.-based company were down $0.13, or 2.88%, at $4.39 on volume of 98,885 shares versus the three-month running average of 50,150 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.